HUTCHMED (China) Limited (LON:HCM - Get Free Report) shares crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 289.47 ($3.76) and traded as high as GBX 328 ($4.26). HUTCHMED shares last traded at GBX 323 ($4.19), with a volume of 192,043 shares.
HUTCHMED Stock Performance
The stock's 50 day moving average price is GBX 279.96 and its 200 day moving average price is GBX 289.70. The company has a market capitalization of £2.76 billion, a P/E ratio of -8,075.00 and a beta of 0.76. The company has a debt-to-equity ratio of 11.78, a quick ratio of 2.97 and a current ratio of 2.81.
About HUTCHMED
(
Get Free Report)
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.
Recommended Stories
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
